Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

@article{Zambrowicz2013EffectsOL,
  title={Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.},
  author={Brian P. Zambrowicz and Zhi-Ming Ding and Ike Ogbaa and Kenny Frazier and Phillip Lee Banks and Anne Turnage and Joel Freiman and Melinda Smith and Dennis A Ruff and Arthur D. Sands and David R. Powell},
  journal={Clinical therapeutics},
  year={2013},
  volume={35 3},
  pages={273-285.e7}
}
BACKGROUND Combination therapy is required to provide adequate glycemic control in many patients with type 2 diabetes mellitus (T2DM). Because sodium-dependent glucose transporter (SGLT)-1 inhibition results in an increased release of glucagon-like peptide (GLP)-1, and because dipeptidyl peptidase (DPP)-4 inhibitors prevent its inactivation, the 2 mechanisms together provide an intriguing potential combination therapy. OBJECTIVES This combination was explored in preclinical models and then… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…